In what ways does lurbinectedin improve treatment specificity?

How does lurbinectedin differ from other chemotherapy drugs?

Lurbinectedin binds the minor groove of DNA in tumor cells and inhibits active transcription by displacing oncogenic transcription factors. This action disrupts the tumor microenvironment and cuts off the recruitment of tumor-associated macrophages, which reduces inflammation and tumor support. [1]

When does lurbinectedin appear in treatment guidelines?

Lurbinectedin gained accelerated FDA approval in June 2020 for metastatic small cell lung cancer after platinum-based chemotherapy. It is listed as a preferred option in NCCN guidelines for patients who have progressed following first-line therapy. [2]

What clinical data show its effectiveness against small cell lung cancer?

In the phase II basket trial, patients receiving 3.2 mg/m² lurbinectedin as a single agent reached an overall response rate of 35.2 percent and a duration of response of 5.3 months. The phase III ATLANTIS study later reported a 53 percent objective response rate in combination with doxorubicin. [2][3]

What side effects are patients most concerned about?

Patients report neutropenia, fatigue, and gastrointestinal effects as common complaints. Neutropenia occurs in 79 percent of patients, 46 percent of which is grade 3 or 4. Fatigue occurs in 77 percent and gastrointestinal discomfort in 55 percent. [1]

How does lurbinectedin improve treatment specificity?

Lurbinectedin shows selective activity against transcription-dependent tumor cells. Its binding displaces oncogenic transcription factors from DNA, which is more selective than broad-spectrum DNA damaging agents such as cisplatin. This focus reduces off-target effects on resting cells. [1]

When does the patent expire?

Lurbinectedin belongs to tetrahydroisoquinoline compounds covered by US Patent 8,952,037. The compound itself is covered until 2031. The formulation patent expires in 2035. [4]

Who makes lurbinectedin?

Pharma Mar develops and markets lurbinectedin under the brand name Zepzelca in partnership with Jazz Pharmaceuticals. [4]

When does lurbinectedin appear in treatment guidelines?